Ready for Skin Cancer Drug Launched

Yervoy or ipilimumab, drugs to cope with
melanoma, the deadliest skin
cancer, was approved by the
Food and Drug Administration
(FDA). Previous primary melanoma
therapy is removal of the tumor through surgery. Melanoma usually arises from
pigment-producing skin cells
(melanin) and do not cause pain.
UV radiation is a major cause of
melanoma. Certain types of moles
can turn into melanoma. According to FDA data, in 2020 in
the United States found 68,130
patients who are diagnosed with
melanoma and 8,700 people of
whom died. Yervoy work to hold a molecule
called CTLA-4 is believed to
weaken the immune system so
the body's ability to fight cancer
disrupted. Drug production Bristol-Myers
Squibb has been evaluated
against 676 clinical melanoma
patients whose cancer has
spread or can not be dissected
again. All patients noted to respond to other types of
melanoma therapy that is also
FDA approved. In the trial against Yervoy, the
life expectancy of patients
reached 10 months, longer than
patients not taking the drug,
which is 6.5 months. Side effects
experienced by patients include fatigue, diarrhea, skin flushing
and inflammation of internal
organs. Approximately 13 percent of
patients reported experiencing a
fatal autoimmune reaction. So
the FDA recommends that
physicians who prescribe these
drugs provide a detailed explanation to the patient,
especially the side effects.